Ann: AusCann to Commence Cannabinoid Trial in Spinal Cord Injury, page-4

This company is entering a new era.

Sliced the guts out of excessive expenditure, developing new programs whilst using the extensive database of knowledge accumulated in this space over the years.
Don't underestimate the potential of the recent acquisition. This market is massive and once AC8 have a foothold with their initial products numerous other avenues will evolve. Plus the products will be applicable in the global space.
Forget about the share price in the short term, by the end 2022, the market will see the true potential of this company and the share price will be adjusted upwards accordingly.